NCT01582425已完成1 期
A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Methadone in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Composite of pharmacokinetics (PK) of plasma for R-methadone and S-methadone: AUClast, AUCinf, and Cmax
研究概览
简要总结
The primary purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics (PK) of methadone after single dose administration. The secondary purpose is to assess the safety and tolerability of isavuconazole alone and in combination with methadone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subject has a body weight of at least 45 kg and has a body mass index (BMI) of 18 to 32 kg/m2, inclusive
- •Results for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be ≤ upper limit of normal and total bilirubin must be ≤ 1.5 mg/dL
- •The female subject agrees to sexual abstinence, or is surgically sterile, postmenopausal (defined as at least 2 years at Screening without menses), or using a medically acceptable double barrier method (e.g. spermicide and diaphragm, or spermicide and condom) to prevent pregnancy and agrees to continue using this method from Screening until 3 weeks after the follow-up visit at the end of the study; and is not lactating or pregnant as documented by negative pregnancy tests at Screening and Day -1
- •The male subject agrees to sexual abstinence, is surgically sterile, or is using a medically acceptable method to prevent pregnancy and agrees to continue using this method from Screening until 3 weeks after the follow-up visit at the end of the study
排除标准
- •The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of Long QT syndrome (suggested by sudden death of a close relative at a young age due to possible or probable cardiac causes)
- •The subject has a positive result for hepatitis C antibodies, hepatitis B surface antigen at Screening or is known to be positive for human immunodeficiency virus (HIV)
- •The subject has a known or suspected allergy to any of the components of the trial products including methadone or the azole class of compounds, or a history of multiple and/or severe allergies to drugs or foods, or a history of severe anaphylactic reactions
- •The subject is a smoker (any use of tobacco or nicotine containing products) within 6 months prior to Screening
- •The subject has had treatment with prescription drugs or complementary and alternative medicines within 14 days prior to Day -1, or over-the-counter medications within 1 week prior to Day -1, with the exception of acetaminophen up to 2 g/day
- •The subject has a recent history (within the last 2 years) of drug or alcohol abuse, or a positive drug and/or alcohol screen
研究组 & 干预措施
Isavuconazole and methadone
Experimental
Single dose of methadone on Days 1 and 20, isavuconazole 3 times a day (TID) on Days 16-17 as a loading dose, isavuconazole once a day (QD) on Days 18-28
干预措施: Isavuconazole (Drug)
Isavuconazole and methadone
Experimental
Single dose of methadone on Days 1 and 20, isavuconazole 3 times a day (TID) on Days 16-17 as a loading dose, isavuconazole once a day (QD) on Days 18-28
干预措施: Methadone (Drug)
结局指标
主要结局
Composite of pharmacokinetics (PK) of plasma for R-methadone and S-methadone: AUClast, AUCinf, and Cmax
时间窗: Days 1 and 20
Area under the curve (AUC) from time of dosing to last quantifiable concentration (AUClast ), AUC from time 0 extrapolated to infinity (AUCinf), maximum concentration (Cmax)
次要结局
- Composite of pharmacokinetics (PK) of plasma for R-methadone and S-methadone : tmax,t1/2, Vz/F, and CL/F(Days 1 and 20)
- PK of plasma isavuconazole: trough concentration (Ctrough)(Days 18 and Days 21 through 29)
- Composite of PK of plasma isavuconazole: AUC during the time interval between consecutive dosing (AUCtau), Cmax, and tmax(Days 19 and 20)
- Safety assessed by recording of adverse events, laboratory evaluations, electrocardiograms (ECGs) and vital signs(Up to Day 36)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult SubjectsPharmacokinetics of IsavuconazolePharmacokinetics of DextromethorphanHealthy Adult VolunteersNCT01651325Astellas Pharma Global Development, Inc.24
已完成
1 期
Drug Interaction Study of Isavuconazole and DigoxinPharmacokinetics of IsavuconazolePharmacokinetics of DigoxinHealthy VolunteersNCT01582412Astellas Pharma Global Development, Inc.24
已完成
1 期
A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult SubjectsHealthy SubjectsPharmacokinetics of IsavuconazolePharmacokinetics of Plasma Mycophenolic Acid (MPA)Pharmacokinetics of Plasma Phenolic Glucuronide of MPA (MPAG)NCT01711489Astellas Pharma Global Development, Inc.24
已完成
1 期
Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male SubjectsPharmacokinetics of IsavuconazolePharmacokinetics of S- and R-warfarinPharmacodynamics of WarfarinHealthy VolunteersNCT01657825Astellas Pharma Global Development, Inc.20
已完成
1 期
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult SubjectsHealthy SubjectsPharmacokinetics of IsavuconazolePharmacokinetics of PrednisoloneNCT01711827Astellas Pharma Global Development, Inc.21